JP2008542365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542365A5 JP2008542365A5 JP2008514586A JP2008514586A JP2008542365A5 JP 2008542365 A5 JP2008542365 A5 JP 2008542365A5 JP 2008514586 A JP2008514586 A JP 2008514586A JP 2008514586 A JP2008514586 A JP 2008514586A JP 2008542365 A5 JP2008542365 A5 JP 2008542365A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- yloxy
- benzyl
- piperidin
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 1-methyl-piperidin-4-yloxy Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000019906 panic disease Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 3
- 101150104680 MCH1 gene Proteins 0.000 claims 3
- 206010027940 Mood altered Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010033664 Panic attack Diseases 0.000 claims 3
- 101100382379 Rattus norvegicus Cap1 gene Proteins 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 230000009286 beneficial effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims 3
- 230000007510 mood change Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- FDPKGXQCDURRBM-UHFFFAOYSA-N 4-(4-methoxyphenyl)benzoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(O)=O)C=C1 FDPKGXQCDURRBM-UHFFFAOYSA-N 0.000 claims 2
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- FICBTMWNFWJNQL-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=CC(Cl)=CC=2)=C1 FICBTMWNFWJNQL-UHFFFAOYSA-N 0.000 claims 1
- CJCOBMTYEDBBSY-UHFFFAOYSA-N 2-phenoxybenzamide Chemical compound NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 CJCOBMTYEDBBSY-UHFFFAOYSA-N 0.000 claims 1
- OAGWHNQUCXPGIV-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=CC(C(=O)NCC=2C=C(OC3CCN(C)CC3)C=CC=2)=C1 OAGWHNQUCXPGIV-UHFFFAOYSA-N 0.000 claims 1
- LXWNTLBMNCXRQN-UHFFFAOYSA-N 4'-fluoro-1,1'-biphenyl-4-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(F)C=C1 LXWNTLBMNCXRQN-UHFFFAOYSA-N 0.000 claims 1
- VXMLQXJQYHWFNO-UHFFFAOYSA-N 4-(3-chlorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=C(Cl)C=CC=2)=C1 VXMLQXJQYHWFNO-UHFFFAOYSA-N 0.000 claims 1
- HIZAKWSGPSDQAZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 HIZAKWSGPSDQAZ-UHFFFAOYSA-N 0.000 claims 1
- CTZYDPNPAYTPAJ-UHFFFAOYSA-N 4-(4-fluoro-3-methylphenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=C(C)C(F)=CC=2)=C1 CTZYDPNPAYTPAJ-UHFFFAOYSA-N 0.000 claims 1
- QTCDZQVGZSUQBS-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 QTCDZQVGZSUQBS-UHFFFAOYSA-N 0.000 claims 1
- BVJKDGKGYCBMNN-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)NCC=2C=C(OC3CCN(C)CC3)C=CC=2)C=C1 BVJKDGKGYCBMNN-UHFFFAOYSA-N 0.000 claims 1
- CREKGPKHHFBOBC-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)N(C)CC=2C=C(OC3CCN(C)CC3)C=CC=2)C=C1 CREKGPKHHFBOBC-UHFFFAOYSA-N 0.000 claims 1
- SPQOKMMLLGTJJL-UHFFFAOYSA-N 4-(4-methylphenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)=C1 SPQOKMMLLGTJJL-UHFFFAOYSA-N 0.000 claims 1
- PJDYFSZUHGVJRM-UHFFFAOYSA-N 4-benzyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(CC=3C=CC=CC=3)=CC=2)=C1 PJDYFSZUHGVJRM-UHFFFAOYSA-N 0.000 claims 1
- YLRKXJUMQVWTOI-UHFFFAOYSA-N 4-cyclohexyl-n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C=1C=C(C2CCCCC2)C=CC=1C(=O)N(C)CC(C=1)=CC=CC=1OC1CCN(C)CC1 YLRKXJUMQVWTOI-UHFFFAOYSA-N 0.000 claims 1
- ZXQYZHKJAOBIOV-UHFFFAOYSA-N 4-phenoxy-n-[(3-piperidin-4-yloxyphenyl)methyl]benzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC1CCNCC1 ZXQYZHKJAOBIOV-UHFFFAOYSA-N 0.000 claims 1
- RISSPRUZBRTULC-UHFFFAOYSA-N 4-phenoxy-n-[[3-(1-propylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(CCC)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 RISSPRUZBRTULC-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- KQQFOGNNTZAYAL-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-1-[3-(1-methylpiperidin-4-yl)oxyphenyl]methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=C3OCOC3=CC=2)=C1 KQQFOGNNTZAYAL-UHFFFAOYSA-N 0.000 claims 1
- YVEQXBUNXFOMPK-UHFFFAOYSA-N n-[[3-(1-benzylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC(CC1)CCN1CC1=CC=CC=C1 YVEQXBUNXFOMPK-UHFFFAOYSA-N 0.000 claims 1
- PQANLFYFLBRNSR-UHFFFAOYSA-N n-[[3-(1-cyclopropylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC(CC1)CCN1C1CC1 PQANLFYFLBRNSR-UHFFFAOYSA-N 0.000 claims 1
- AFMXBORFJZKSOK-UHFFFAOYSA-N n-[[3-(1-ethylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(CC)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 AFMXBORFJZKSOK-UHFFFAOYSA-N 0.000 claims 1
- MRBZBRGOCVOJJT-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-phenoxyphenyl)methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 MRBZBRGOCVOJJT-UHFFFAOYSA-N 0.000 claims 1
- QAIVOSFJXAMSDU-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-phenylphenyl)methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 QAIVOSFJXAMSDU-UHFFFAOYSA-N 0.000 claims 1
- RAXRPWHEVIYGCB-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-propan-2-ylphenyl)methanamine Chemical compound C1=CC(C(C)C)=CC=C1CNCC1=CC=CC(OC2CCN(C)CC2)=C1 RAXRPWHEVIYGCB-UHFFFAOYSA-N 0.000 claims 1
- BBUSGCSBLGJHHL-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-3-phenoxybenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=C(OC=3C=CC=CC=3)C=CC=2)=C1 BBUSGCSBLGJHHL-UHFFFAOYSA-N 0.000 claims 1
- KSKVZHOHVWXVIP-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-(4-methylsulfonylphenyl)benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 KSKVZHOHVWXVIP-UHFFFAOYSA-N 0.000 claims 1
- KAAHTYMQPGOFRE-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-[4-(trifluoromethoxy)phenyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 KAAHTYMQPGOFRE-UHFFFAOYSA-N 0.000 claims 1
- VMSMZDPNNGYOLL-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenylbenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 VMSMZDPNNGYOLL-UHFFFAOYSA-N 0.000 claims 1
- YNQVBDCUPBKVPE-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenylmethoxybenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1 YNQVBDCUPBKVPE-UHFFFAOYSA-N 0.000 claims 1
- IADYROZDLAWMHG-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-thiophen-3-ylbenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C2=CSC=C2)=C1 IADYROZDLAWMHG-UHFFFAOYSA-N 0.000 claims 1
- NQQFNYNBNBXFNX-UHFFFAOYSA-N n-[[3-[(4-methylpiperazin-1-yl)methyl]phenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(C)CCN1CC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 NQQFNYNBNBXFNX-UHFFFAOYSA-N 0.000 claims 1
- IGLJXAOHZMBCMN-UHFFFAOYSA-N n-[[3-[1-(2,2-dimethylpropyl)piperidin-4-yl]oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(CC(C)(C)C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 IGLJXAOHZMBCMN-UHFFFAOYSA-N 0.000 claims 1
- SZDZVNAICFHQQD-UHFFFAOYSA-N n-[[3-[1-(oxolan-3-yl)piperidin-4-yl]oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC(CC1)CCN1C1CCOC1 SZDZVNAICFHQQD-UHFFFAOYSA-N 0.000 claims 1
- DCOVPKWLIJKMTM-UHFFFAOYSA-N n-ethyl-n-[[3-(1-ethylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)N(CC)CC(C=1)=CC=CC=1OC1CCN(CC)CC1 DCOVPKWLIJKMTM-UHFFFAOYSA-N 0.000 claims 1
- CVMJFDVTAZFJLW-UHFFFAOYSA-N n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-phenoxyphenyl)methanamine Chemical compound C=1C=CC(OC2CCN(C)CC2)=CC=1CN(C)CC(C=C1)=CC=C1OC1=CC=CC=C1 CVMJFDVTAZFJLW-UHFFFAOYSA-N 0.000 claims 1
- GBQVRCQAGWZRJP-UHFFFAOYSA-N n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)N(C)CC(C=1)=CC=CC=1OC1CCN(C)CC1 GBQVRCQAGWZRJP-UHFFFAOYSA-N 0.000 claims 1
- PKMRIBLWFLQQTE-UHFFFAOYSA-N n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenylbenzamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)N(C)CC(C=1)=CC=CC=1OC1CCN(C)CC1 PKMRIBLWFLQQTE-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68583205P | 2005-05-31 | 2005-05-31 | |
| PCT/SE2006/000621 WO2006130075A1 (en) | 2005-05-31 | 2006-05-29 | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008542365A JP2008542365A (ja) | 2008-11-27 |
| JP2008542365A5 true JP2008542365A5 (https=) | 2009-07-16 |
Family
ID=37481914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514586A Pending JP2008542365A (ja) | 2005-05-31 | 2006-05-29 | 新規なｍｃｈｒ１アンタゴニスト並びにｍｃｈｒ１媒介状態及び障害の処置のためのそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080269275A1 (https=) |
| EP (1) | EP1891065A4 (https=) |
| JP (1) | JP2008542365A (https=) |
| KR (1) | KR20080011677A (https=) |
| CN (1) | CN101184753A (https=) |
| AU (1) | AU2006253049B2 (https=) |
| BR (1) | BRPI0610907A2 (https=) |
| CA (1) | CA2610671A1 (https=) |
| IL (1) | IL187248A0 (https=) |
| MX (1) | MX2007014464A (https=) |
| NO (1) | NO20076695L (https=) |
| WO (1) | WO2006130075A1 (https=) |
| ZA (1) | ZA200709922B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1976828T (lt) | 2005-12-29 | 2017-04-25 | Celtaxsys, Inc. | Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai |
| CN101400677A (zh) * | 2006-01-06 | 2009-04-01 | 阿斯利康(瑞典)有限公司 | 化合物 |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| AU2011275547B2 (en) | 2010-07-06 | 2015-10-29 | Astrazeneca Ab | Therapeutic agents 976 |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| CA2906035A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| WO2014152536A2 (en) * | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH377824A (de) * | 1959-08-28 | 1964-05-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen |
| CH377826A (de) * | 1959-08-28 | 1964-05-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen |
| ZA829150B (en) * | 1981-12-14 | 1984-07-25 | American Home Prod | Benzo-fused heterocyclic compounds |
| IL69392A (en) * | 1982-08-13 | 1987-01-30 | Sanofi Sa | N-oxide nicotinamide derivatives,their preparation and pharmaceutical compositions containing them |
| FR2531704B1 (fr) * | 1982-08-13 | 1985-08-09 | Sanofi Sa | Amides d'acides (hetero)aromatiques n-substitues, leurs sels, procede pour leur preparation et compositions pharmaceutiques en contenant |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| EP1218336A2 (en) * | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| JP4025200B2 (ja) * | 2000-12-22 | 2007-12-19 | シェーリング コーポレイション | ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用 |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7601868B2 (en) * | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
| WO2005077903A2 (en) * | 2004-02-09 | 2005-08-25 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted tetrahydroisoquinoline analogues |
-
2006
- 2006-05-29 CA CA002610671A patent/CA2610671A1/en not_active Abandoned
- 2006-05-29 US US11/914,400 patent/US20080269275A1/en not_active Abandoned
- 2006-05-29 AU AU2006253049A patent/AU2006253049B2/en not_active Ceased
- 2006-05-29 EP EP06747815A patent/EP1891065A4/en not_active Withdrawn
- 2006-05-29 BR BRPI0610907-1A patent/BRPI0610907A2/pt not_active IP Right Cessation
- 2006-05-29 JP JP2008514586A patent/JP2008542365A/ja active Pending
- 2006-05-29 KR KR1020077027793A patent/KR20080011677A/ko not_active Withdrawn
- 2006-05-29 CN CNA2006800191464A patent/CN101184753A/zh active Pending
- 2006-05-29 WO PCT/SE2006/000621 patent/WO2006130075A1/en not_active Ceased
- 2006-05-29 MX MX2007014464A patent/MX2007014464A/es not_active Application Discontinuation
-
2007
- 2007-11-08 IL IL187248A patent/IL187248A0/en unknown
- 2007-11-16 ZA ZA200709922A patent/ZA200709922B/xx unknown
- 2007-12-28 NO NO20076695A patent/NO20076695L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542365A5 (https=) | ||
| JP5035238B2 (ja) | 神経治療アゾール化合物 | |
| JP2005526723A5 (https=) | ||
| CA2702933A1 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| AU7446600A (en) | Novel diarylamide derivatives and use thereof as medicines | |
| JP6321825B2 (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| RU2012129737A (ru) | Замещенные бензамидные производные | |
| JP2009539762A (ja) | Ｈ３受容体のテトラリン拮抗薬 | |
| AU2013309124B2 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| JP2008543923A (ja) | ヒスタミン−３受容体アンタゴニスト | |
| JP2010506918A5 (https=) | ||
| JP2011517443A5 (https=) | ||
| JP2011500697A5 (https=) | ||
| JP2005524620A (ja) | ５−ｈｔ２ｃ受容体活性を有する環状ウレア誘導体 | |
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| CA2529126A1 (en) | Azetidine compounds | |
| RU2424227C2 (ru) | Антагонист рецептора s1p3 | |
| JP2006519812A (ja) | フェニルスルホン誘導体およびｃｎｓ障害の治療におけるその使用 | |
| EP0344577B1 (en) | Butenoic or propenoic acid derivatives | |
| JP2009514899A5 (https=) | ||
| JP2009515934A (ja) | 新規なキナゾリン誘導体及びこれらの医学的使用 | |
| JP2002509135A (ja) | 神経細胞カルシウムチャンネルの活性の調節剤としてのアミノスルホニルベンズアミド誘導体 | |
| BRPI0711971A2 (pt) | fluoretil uréias terapêuticas | |
| NZ551509A (en) | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | |
| JP2006117568A (ja) | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |